Compare Citius Pharmaceuticals Inc (CTXR) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Match Group Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Match Group Inc trades at $39.6 (market cap $8.94B). The key difference: Match Group Inc is far larger — about 610.7× Citius Pharmaceuticals Inc's market cap, and Match Group Inc pays a 2.09% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MTCH | |
|---|---|---|
Market Cap | $14.64M | $8.94B |
Sector | Health | Media |
52-Week High | $1.82 | $39.32 |
52-Week Low | $0.53 | $28.90 |
Enterprise Value | $10.86M | $11.89B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
MTCH trades at $38.54, down 0.8% on the day, with a bullish technical signal from moving averages and strong analyst support (17 buy ratings, 0 sell). The company shows solid fundamentals with 4% revenue growth in Q1 2026, an 18.83% net income margin, and positive cash flow trends. Recent news highlights Tinder's turnaround progress and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents upside potential with a consensus price target of $41.63 (8% upside), supported by improving profitability and cash flow generation. Key risks include Tinder's user decline offset by price increases, high debt levels ($3.85B), and competitive pressures in the dating app space. The current valuation at 14.71 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
